marine drugs

MDPI

Article

Peptide Modulator of TRPV1 Channel Increases Long-Term Potentiation in the Hippocampus and Reduces Anxiety and Fear in Mice Under Acute Stress

Vladimir M. Pavlov [1,2], Anastasia Yu. Fedotova [1,2], Victor A. Palikov [1,2], Yulia A. Logashina [3], Kamilla I. Zagitova [3], Igor A. Dyachenko [1,2], Alexander V. Popov [3,4] and Yaroslav A. Andreev [3,*]

1 Branch of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 6 Nauki Avenue, 142290 Pushchino, Moscow region, Russia; dyachenko@bibch.ru (I.A.D.)
2 Pushchino Branch of the Federal State Budgetary Educational Institution of Higher Education "Russian Biotechnological University (BIOTECH University)", Prospekt Nauki, 3, 142290 Pushchino, Moscow region, Russia
3 Shemyakin—Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Ul. Miklukho-Maklaya 16/10, 117997 Moscow, Russia
4 Kurchatov Medical Primatology Center of National Research Center «Kurchatov Institute», 354376 Sochi, Russia
* Correspondence: aya@ibch.ru

Abstract

One of the attractive targets for the relief of stress conditions is TRPV1, which is expressed mostly in primary afferent neurons (nociceptors) and in the central nervous system, mainly in the cortex and hippocampus. We evaluated the action of a potent low-molecular-weight antagonist of TRPV1 (AMG517) and peptide modulator of this channel (APHC3) on long-term potentiation (LTP) and Paired-Pulse Ratio (PPR) in the CA3-CA1 region of the hippocampus of mice. In vivo, we used intranasal administration to provide effective peptide delivery into the brain and analyzed the effects of APHC3 in acute stress tests in comparison with intramuscular administration of APHC3, AMG517, and the reference anxiolytic drug Fabomotizole (Fab). In electrophysiology studies, APHC3 significantly enhanced LTP and PPR, while AMG517 enhanced only PPR. Intranasal administration of APHC3 to mice provided a moderate anxiolytic effect in the single dose (0.01 mg/kg). Intramuscular administration of APHC3 and AMG517 significantly reduced acute stress in mice equal to the reference drug Fab. Thus, TRPV1 modulation in either the peripheral or central nervous system is sufficient to produce an anxiolytic-like effect, likely through distinct underlying mechanisms.

Keywords: TRPV1; sea anemone peptide; toxin; long-term potentiation (LTP); paired-pulse ratio (PPR); anxiolytic effect; anxiety; fear

Academic Editors: David Adams and Sebastien Dutertre

Received: 27 November 2025
Revised: 14 January 2026
Accepted: 27 January 2026
Published: 31 January 2026

1. Introduction

Transient receptor potential vanilloid receptor 1 (TRPV1) is a non-selective ion channel activated by various stimuli such as high temperature, pH changes, endogenous derivatives of polyunsaturated fatty acids, and exogenous ligands [1,2]. TRPV1 is widely expressed in the brain, including the cerebral cortex, hippocampus, and hypothalamus, and was found in neuronal cell bodies, dendrites, and astrocytes [3]. It is interesting that the expression of TRPV1 in the human brain is several fold higher than in rodents [4]. TRPV1 plays a significant role in nociception, detecting thermal and chemical stimuli. In contrast to the

well-known function of TRPV1 in the PNS, the role of these channels in various conditions in the central nervous system remains poorly understood. Activation of this channel on the free ending of nociceptors leads to initiation of pain signals and initiation of local neurogenic inflammation [5]. In the brain, TRPV1 is most probably involved in the regulation of synaptic transmission and plasticity [6–9]. Exogenous and endogenous TRPV1 agonists have been shown to enhance depressive and anxiety-like behavior in animals [10,11]. Whereas TRPV1 knockout or administration of antagonists was found to produce an antidepressant-like and anxiolytic effect. This effect is associated with the involvement of TRPV1 in neuronal plasticity through its effects on long-term potentiation (LTP) and long-term depression (LTD) [3]. Generally, depending on the type of synapse, TRPV1 activation on the pre- or postsynaptic membrane can lead to opposite effects—strengthening or weakening neuronal communication [3]. However, the mechanisms of TRPV1 regulation of synaptic function in brain and behavior are not fully understood [3]. Activation of the TRPV1 channels facilitates excitatory transmission in the central nervous system, which promotes LTP [12] but also mediates long-term depression at synapses on hippocampal interneurons [9]. TRPV1-deficient mice showed reduced hippocampal LTP accompanied by reduced anxiety and conditioned fear [8].

TRPV1 may be a potential target for the treatment of various psychiatric conditions, such as depression and anxiety. Stress is one of the etiological factors in the development of these conditions [13]. TRPV1 knockout mice exhibit less anxiety and reduced fear responses, which are associated with a decrease in LTP, confirming the link between TRPV1 and the development of fear [8,14]. TRPV1 antagonist capsazepine has been found to have anxiolytic activity when administered systemically, while the agonist olvanil, on the other hand, exhibited an angiogenic effect [15]. Moreover, inhibition of TRPV1 in the CNS by injecting the antagonist into the medial prefrontal cortex reduces anxiety in rats [16].

One of the challenges in investigating potential candidates is the potential side effects of TRPV1 antagonists in clinical trials, including their hyperthermic effects [17–19]. For example, substance AMG517 inhibits TRPV1 in the nanomolar range (IC_{50} 0.9 nM), possesses significant analgesic activity accompanied by good pharmacological properties, but causes a significant increase in humans core body temperature in Phase I of clinical trials [18,20,21]. However, antagonists that do not cause hyperthermia have been identified. One such antagonist is the sea anemone peptide APHC3 [22], which exhibits a complex effect on the TRPV1 channel, inhibiting robust activation of the channel but potentiating response to low concentrations of capsaicin [23]. APHC3 has no effect on TRPA1, TRPV3, TRPM8, ASIC1a, ASIC3 channals, p2X3 receptor and on membranes of CHO cells and X.laevis oocytes [24]. APHC3 also was found to block the response of TRPV1 to acidification (pH 5.5) in calcium imaging experiments but also potentiated response to acidification [pH 5.5–6.2] in patch-clamp experiments [23,24]. APHC3 produced significant analgesic and anti-inflammatory activity accompanied by a moderate hypothermic effect [24–27]. Additionally, APHC3 was found to significantly reduce the susceptibility to apoptosis of neuron-like cells, including stress conditions such as the accumulation of cytotoxic variant of alpha-synuclein A53T [28]. Preliminary experiments revealed anxiolytic effects of the peptide [29].

Animal studies indicated that stress responses can induce behavioral changes resembling the core symptoms of depression and anxiety in humans, such as anhedonia, decreased self-care, and sleep disturbances [30,31]. In this study, we elucidated the involvement of TRPV1 channels in acute stress and the potential effects of their inhibition. We analyzed the effects of two TRPV1 antagonists (AMG517 and APHC3) on Paired-Pulse Ratio (PPR) and field excitatory postsynaptic potentials after induction of long-term potentiation (LTP) in the hippocampal CA3-CA1 areas. Additionally, we evaluated response to acute

stress in the elevated plus maze and light/dark chamber tests after treatment by AMG517, APHC3, and the anxiolytic and neuroprotective drug Fabomotizole (Fab) [32,33]. Peptide APHC3 was administered intramuscularly (i.m.) to restrict the action on the peripheral nervous system and intranasally to provide the effect of the peptide on the brain. Both AMG517 and APHC3 improved behavioral performance in animals in stress tests on the same level as Fab, confirming the significant role of the TRPV1 channel in this process. It is interesting that i.m. administration of peptide APHC3 showed a more significant and robust effect than intranasal. This result highlights the significant role of peripheral nociceptors in the anxiolytic effect of TRPV1 modulators.

2. Results

2.1. Effects of Two TRPV1 Antagonists on Long-Term Potentiation (LTP) and Paired-Pulse Ratio (PPR) in the Hippocampal CA3-CA1 Areas

TRPV1 channels are extensively studied in nociceptive neurons of the peripheral nervous system, but their role in the brain is far less understood. Activation of TRPV1 reportedly regulates neurotransmitter release at several central synapses, whereas inhibition generally showed no effect on LTP and LTD in the hippocampus. Usually, antagonists of all modes of activation (capsezepin) were used in experiments on brain slices [8,9,34] and none of the modulators that could differently affect distinct modes of activation were analyzed in such experiments. We evaluated the effects of antagonist AMG517 and peptide modulator APHC3 on LTP.

Using the local field potential method [35], the EPSP amplitude was measured 50–60 min after induction of long-term potentiation using high-frequency stimulation, which was applied 15 min after the start of the experiment (Figures 1A and 2A). AMG517 showed some tendency to facilitate LTP, but the effect was not statistically significant (Figure 1A,B), which correlates to previous reports [8,9,34]. Application of vehicle (0.05% DMSO in ACSF) resulted in a mean value of 128.9 ± 6.9% (n = 5), while the AMG517 (10 nM) group's value was 144.2 ± 2.2 (n = 5, two-tailed t-test p = 0.064). Nevertheless, PPR analyses revealed that AMG517 application produced paired-pulse facilitation (PPF) and could improve short-term plasticity.



Figure 1. LTP and PPR in CA3-CA1 synapses of mice after preincubation with AMG 517. (**A**) LTP induced by HFS in the CA3-CA1 region of the hippocampus of control (gray circles) and AMG517-treated (blue circles) slices. (**B**) Sample fEPSPs before HFS and 40 min after HFS (gray—control (0.05% DMSO in ACSF, Ctrl), blue—treated with 10 nM AMG517. (**C**) Graph summary of LTP magnitude 50–60 min after HFS stimulation. (**D**) The paired-pulse ratio of fEPSPs showed a partial presynaptic AMG517-mediated effect. AMG517 (10 nM) elicited significant PPRs facilitation (blue, n = 6) compared with control (gray, n = 5) at 100, 200, 650, and 850 ms intervals. The data are shown as the mean ± SD, horizontal lines are mean values of the data, squares–medians. *—$p < 0.05$ two-tailed two-sample t-test.



Figure 2. LTP and PPR in CA3-CA1 synapses of mice after preincubation with different concentrations of APHC3. (**A**) LTP induced by HFS in the CA3-CA1 region of the hippocampus of control (gray circles) and APHC3-treated (brown circles) slices. (**B**) Sample fEPSPs before HFS and 40 min after HFS: black—control (Ctrl), brown—treated with 300 nM APHC3. (**C**) Graph summary of LTP magnitude 50–60 min after HFS stimulation. (**D**) The paired-pulse ratio of fEPSPs shows mostly a presynaptic APHC3-mediated effect. PPRs for control (white, $n = 7$), 30 nM APHC3 (yellow, $n = 5$), 300 nM APHC3 (orange, $n = 6$), and 900 nM APHC3 (brown, $n = 4$). APHC3 (30 nM) differs significantly at 50, 100, 200, 250, and 650 ms intervals. The data are shown as the mean ± SD, horizontal lines are mean values of the data, squares–medians. *—$p < 0.05$ two-tailed two-sample *t*-test.

APHC3 statistically significantly increased LTP at concentrations of 30 and 300 nM (two-tailed *t*-test $p = 0.0289$ and 0.02257, correspondingly). The control group's value was 128.7 ± 5.4% ($n = 7$), while the APHC3 (30 nM and 300 nM) group's values were 158.8 ± 15 ($n = 5$) and 142 ± 1.7% ($n = 6$) (Figure 2B). Concentration 900 nM showed no significant effect (mean value 146.5 ± 11.7, two-tailed *t*-test $p = 0.073$). Only at a concentration of 30 nM APHC3 did PPR significantly increase, while 300 and 900 nM showed no effect (Figure 1D).

These results suggest a positive effect of the APHC3 peptide at a concentration of 30–300 nM on synaptic plasticity. APHC3 significantly increased short-term potentiation (determined as PPF) at a concentration of 30 nM and LTP at 30–300 nM. However, the specific mechanisms require further study, particularly the effects on synaptic and extrasynaptic NMDA receptors and the synaptic microenvironment. Such as changes in receptor distribution and synapse coverage by astrocytes, the efficiency of the astrocytic network, and the impact on calcium activity.

2.2. Anxiety-like Behavior in Mice

The Elevated Plus Maze

Peptide APHC3 facilitated LTP on brain slices; therefore, delivery of the peptide in the brain could have an effect on anxiety-like behavior. The intranasal administration of peptides is a well-known way of non-invasive delivery of peptides in the brain, bypassing the blood–brain barrier [36,37]. Thus, we tested peptide APHC3 at different doses (0.005–1 mg/kg) in the elevated plus maze test in comparison with intramuscular (i.m.) administration of anxiolytic drug Fabomotizole (Fab, 2.4 mg/kg) (Figure 3). There was no

difference in behavior between groups of mice after administration of saline by different routes (intranasal vs. intramuscular). APHC3 significantly increased the number of interactions with open areas at doses of 0.005–0.1 mg/kg, with a maximum effect at 0.01 mg/kg, while a dose of 1 mg/kg had no effect. Nevertheless, only a dose of 0.01 mg/kg showed a statistically significant effect on time spent in open areas (Figure 3B,C). Animals that received APHC3 at a dose of 0.01 mg/kg showed a 113% increase in time spent in open areas. Whereas interaction with the open areas increased by 91.2% compared to the control group (Figure 3B). Additionally, 75% of the animals visited the open arms of the maze, compared to 50% in the control group. Fab (2.4 mg/kg) showed a significant effect in the elevated plus maze test, confirming stated anxiolytic properties.



Figure 3. Elevated plus maze test. Peptide APHC3 was administered intranasally. Groups Saline i.m. and Fab received saline and Fab (2.4 mg/kg) by intramuscular injection. (**A**) Interactions with open areas. (**B**) Time spent in open areas. The results are presented as the mean ± S.D., $n = 8$ for each group; ***, $p < 0.001$; *, $p < 0.05$, vs. saline group (ANOVA followed by a Dunnett's multiple comparisons test). Effects of saline solution are shown by black (i.n.) and grey (i.m.) circles, APHC3 by green triangles, Fab by blue diamonds. Dashed line indicates the complete avoidance of open areas.

To evaluate the role of peripheral inhibition of TRPV1 channels by APHC3, we administered APHC3 (0.01–1 mg/kg, i.m.) in comparison with Fab (2.4 mg/kg, i.m.) and potent TRPV1 antagonist AMG517 (1 mg/kg, i.m.). APHC3 at doses of 0.01 and 1 mg/kg, AMG517, and Fab significantly increased time spent in open areas and the number of interactions with it. Surprisingly, APHC3 at 0.1 mg/kg showed almost no effect on mice behavior (Figure 4). APHC3 at doses of 0.01 and 1 mg/kg increased the number of interactions with the open areas by 114% and 111% and time spent in the open areas by 158% and 179%, which is equal to or non-significantly better than AMG517 and Fab (Figure 4).

2.3. The Light-Dark Chamber

This test is based on a conflict between an animal's natural aversion to bright open spaces and its tendency to explore new environments. We assessed the number of transitions between the light and dark compartments and the time spent in each of them. We analyzed the effects of intranasal and intramuscular administration of different doses of APHC3 compared with Fab (2.4 mg/kg, i.m.) and AMG517 (1 mg/kg, i.m.). Intranasal administration of APHC3 produced a significant effect only at a dose of 0.01 mg/kg and only on time spent in the light chamber.



Figure 4. Elevated plus maze test after intramuscular administration of tested compounds. (**A**) Interactions with open areas. (**B**) Time spent in open areas. The results are presented as the mean ± S.D., $n = 8$ for each group; ***, $p < 0.001$; **, $p < 0.01$, vs. saline group (ANOVA followed by a Dunnett's multiple comparisons test). Effects of saline solution are shown by black circles, APHC3 by green triangles, Fab by blue diamonds, AMG517 by red circles.

Intramuscular administration of APHC3 (0.01 and 1 mg/kg) significantly increased both the number of transitions and time spent in the light chamber (Figure 5). The dose of 0.1 mg/kg of APHC3 showed no statistically significant effect on mice behavior (Figure 6). confirming the results of the elevated plus maze.



Figure 5. Light/dark chamber test. APHC3 and saline were administered intranasally. (**A**) Transitions between chambers. (**B**) Time spent in the light chamber. Results are presented as mean ± SD; ***, $p < 0.001$; **, $p < 0.01$ vs. saline group (ANOVA followed by a Dunnett's multiple comparisons test). Effects of saline solution are shown by black (i.n.) and grey (i.m.) circles, APHC3 by green triangles, Fab by blue diamonds.

Fab and AMG517 produced significant increases both in the number of transitions and in time spent in the light chamber (Figure 6). Administration of APHC3 (0.01 and 1 mg/kg), Fab, or AMG517 produced more than a 2-fold increase in the number of transitions. Fab and AMG517 increased the time spent in the light chamber by 26% and 27%, respectively, while APHC3 (1 mg/kg) increased it by 33%.



Figure 6. Light/dark chamber test. APHC3 and saline were administered intramuscularly. (**A**) Transitions between chambers. (**B**) Time spent in the light chamber. Results are presented as mean ± SD; ***, $p < 0.001$; **, $p < 0.01$ vs. saline group (ANOVA followed by a Dunnett's multiple comparisons test). Effects of saline solution are shown by black circles, APHC3 by green triangles, Fab by blue diamonds, AMG517 by red circles.

3. Discussion

TRPV1 channel is widely expressed in the CNS, especially in the cortex and hippocampus, and could be considered as a target for the treatment of stress-related conditions [1,3,31]. Hippocampal LTP of TRPV1-knockout mice was significantly reduced compared with wild-type mice, underlining the participation of TRPV1 in synaptic plasticity [8]. Activation of TRPV1 by selective agonists (capsaicin or resiniferatoxin) triggers LTD in hippocampal interneurons [9], but enhanced LTP induction in the CA1 region [8]. Acute intraperitoneal administration of capsaicin improved cognitive performance in passive avoidance learning tasks [38]. TRPV1 antagonists did not affect the LTP or LTD itself but could reverse the effects of TRPV1 agonists [9,34]. Nevertheless, TRPV1 knockout mice showed reduced anxiety-like behavior and response to fear [14,39]. The same effect was observed after injection of TRPV1 antagonist in the medial prefrontal cortex of rats [11]. Antagonist of TRPV1, AMG9810, also showed antidepressant effects on mice [40]. Molecular mechanisms of anxiolytic activity of TRPV1 modulators could involve regulation of synaptic transmission and plasticity based on effects on pre-synaptic LTD, post-synaptic LTP, and regulation of activation of GABA-ergic synapses [3].

Our data indicates that APHC3 and AMG517 could bind to both pre- and postsynaptic terminals of the synapse that corresponds to the TRPV1 channel expression profile. We found that AMG517, a potent antagonist of TRPV1, did not produce a significant effect on CA3-CA1 LTP, which corresponds well with data on other all-mode TRPV1 antagonists (Figures 1 and 7). Nevertheless, AMG517 partially facilitated PPR in the CA3-CA1 hippocampal region. Changes in the paired-pulse ratio most often indicate that synaptic plasticity results from a change in neurotransmitter release [41]. Apparently, TRPV1 blocking leads to incomplete removal of Ca^{2+} ions from the synapse in the time between the first and second stimuli, and as a consequence, greater messenger concentration during the second pulse [42]. However, the paired-pulse facilitation via TRPV1 blockade occurred at certain timepoints, which indicates the pathway complexity. The functional TRPV1 channels are present on excitatory CA3 and CA1 pyramidal cell bodies as well as on some inhibitory interneurons (IN) of the CA1 region [9]. Thereby measured field postsynaptic potentials had a multisynaptic nature—excitation from CA3 pyramidal cells spread directly as well as via interneurons (disynaptic mode) to CA1 cells [43,44]. Moreover, disynaptic mode

is a complex process involving excitatory and inhibitory components, the ratio of which changes over time [44]. Therefore, TRPV1 inhibition in hippocampal cells leads to synaptic plasticity through fluctuations in calcium concentration and following neurotransmitter release of multisynaptic pathway CA1 ← CA3 → IN → CA1. The further experiments will help to clarify these molecular mechanisms.



Figure 7. Differential synaptic modulation by the TRPV1 modulator APHC3 and the antagonist AMG517. APHC3 exhibits context-dependent activity (lines with points): it predominantly inhibits TRPV1 (blue blocks) but can potentiate channel currents under conditions of weak activation (pink blocks). In hippocampal slice preparations, APHC3 produced a biphasic concentration-response: low concentrations (left arrow and solid lines) facilitated long-term potentiation (LTP) and increased paired-pulse facilitation (PPF), while high concentrations (right arrow and solid lines) abolished LTP and PPF. In contrast, the small-molecule TRPV1 antagonist AMG517 (dashed lines) consistently suppressed LTP and increased PPF, aligning with reported effects of channel blockade. The divergent effects of APHC3 may arise from distinct actions at pre- versus postsynaptic terminals or from temporally dynamic modulation of calcium dynamics within the synaptic cleft.

Interestingly, TRPV1 activation enhances vesicle recycling and neurotransmitter release, followed by postsynaptic action potential firing [45,46]. TRPV1 agonists can decrease excitatory transmission from CA3 onto IN, which innervate and inhibit CA1 pyramidal cells [9]. Moreover, TRPV1 activation enhances LTP through the GABA-ergic interneuron inputs, showing that TRPV1 agonist-mediated LTP enhancement appears most likely because of pyramidal cell disinhibition via feedforward interneurons [47]. In other words, LTP induction by TRPV1-agonists goes through the CA3 → IN → CA1 pathway.

Peptide APHC3 significantly enhanced LTP at concentrations of 30 and 300 nM but showed no effect at 900 nM. Facilitation of LTP could result from the ability of APHC3 to potentiate weak stimulation of TRPV1, thus mimicking agonist action, while robust channel activation would be blocked. Our data demonstrated that at low concentrations APHC3 increased TRPV1 activation, inducing LTP. However, the rise in peptides' concentration potentially enhanced neurons depolarization and TRPV1 activation to a critical value at which the peptide mode of action changed to inhibition and no LTP was observed. The PPR after APHC3 application changed only for the lowest used concentration, which highlights the similarity to the AMG517 mechanism of short-term plasticity modulation. Interestingly, previous studies of LTP and PPF relationships showed that LTP can be associated with PPF decrease, or the paired-pulse ratio did not change significantly [48]. Therefore, molecular mechanisms underlying the influence of APHC3 on LTP and PPF represent contradictory modes of action, which could be explained by diverse effects of peptide on presynaptic and postsynaptic terminals, namely blocking or potentiating, respectively, depending on the

degree of channel activation. Moreover, the direct CA3 → CA1 pathway could be involved in the PPF increase after application of 30 nM peptide, which requires further studies.

Since the action on the CNS of AMG517 and APHC3 was significant, we tested the anxiolytic effect of these compounds. Anxiety is a multimodal phenomenon caused by various factors with different etiologies, including stressful stimuli, hormonal changes, genetic predispositions, and chronic diseases. These factors initiate stress responses that can lead to various pathological changes in the body [49,50]. The anxiety state can be modeled by a single application of the stress factor for a short period of time. In some cases, the testing environments themselves can act as a stressor [51]. For example, the elevated plus maze is used to study anxiety in rodents based on their instinctive preference for dark burrows and fear of open spaces and heights [52,53]. In the light/dark chamber test, the stressor is the avoidance of brightly lit areas by animals [54].

The anxiolytic pharmacology of TRPV1 antagonists is well-established, with efficacy shown following systemic (e.g., capsazepine; [15]) and targeted intracerebral administration to limbic structures including the hippocampus, periaqueductal gray, and prefrontal cortex [11,55–57]. Importantly, this literature provides precedent for the non-linear, "inverse U-shaped" dose–response curve observed in a study by Aguiar et al. (2009) [16]. Microinjection of capsazepine into the rat prefrontal cortex produced maximal anxiolysis at an intermediate dose (10 nmol/0.2 μL), with significantly reduced efficacy at a higher dose (60 nmol/0.2 μL) [16]. This pattern suggests that optimal TRPV1 antagonism for anxiolytic effect may occur within a specific therapeutic window, beyond which compensatory mechanisms or off-target effects may attenuate the behavioral response.

AMG517 is a low-molecular-weight (Mw ~430 Da) compound that could pass the blood–brain barrier; therefore, we administered it intramuscularly. APHC3 is the peptide (Mw ~6111 Da), and we used intranasal administration to introduce it to the CNS and intramuscular injection to restrict peptide action only to the peripheral nervous system. Intranasal delivery of large peptides to the CNS is indeed inefficient, but it represents the only non-invasive, clinically feasible route for peptides to directly target the brain. The absolute CNS bioavailability for intranasally administered peptides is typically low (<1% of the dose), with a variable fraction also reaching the systemic circulation [58]. Our study aimed to explore this practical route. APHC3 at 0.01 mg/kg significantly increases the number of interactions with open areas and time spent in open areas in the elevated plus maze and time spent in the open chamber in the dark/light chamber test. A decrease or increase in the APHC3 dose led to the disappearance of the effect. This result demonstrates a non-monotonic ("inverse U-shaped") dose–response relationship, which is not consistent with a simple model of limited CNS penetration causing the weak effect. The observation of anxiolytic activity at the lower i.n. dose (0.01 mg/kg) is consistent with direct peptide delivery to the brain. However, a higher i.n. doses (0.1 and 1 mg/kg), intended to increase CNS exposure, abolished the anxiolytic effect—mirroring the biphasic pattern seen in electrophysiological assays (PPR and LTP). This non-monotonic response argues against a simple pharmacokinetic failure (i.e., insufficient CNS delivery) and instead points to a specific pharmacodynamic interaction within the CNS, where efficacy is lost at higher concentrations.

Intramuscular injection of AMG517 (1 mg/kg) and APHC3 (0.01 and 1 mg/kg) produced a significant anxiolytic effect equal to the reference drug, Fabomotizole (Fab) (Figures 4 and 6). Unexpectedly, the APHC3 at a dose of 0.1 mg/kg showed no anxiolytic effect in both models. It is interesting that this dose of APHC3 was found to be optimal to produce maximal analgesic and anti-inflammatory effects in previous studies [24,26]. Moreover, APHC3 at 0.1 mg/kg reduced core body temperature (rectal measuring) [24] that could also affect behavioral output. The hypothermic effect of APHC3 was found to

be non-significant at doses of 0.5 mg/kg and 0.01 mg/kg [24]. As was shown previously, AMG517 can inhibit TRPV1, stably increase body temperature, transiently increase the energy metabolism of the whole body and reduce corticosterone level [18,59,60], and in our experiments it showed significant anxiolytic activity. APHC3 is a 56-residue peptide (~6.1 kDa). Peptides of this size are generally excluded from the CNS by the intact blood–brain barrier (BBB) following systemic (intramuscular or intravenous) administration. Therefore, the robust anxiolytic effect observed after intramuscular injection strongly suggests a mechanism initiated outside the CNS. The non-monotonic response might suggest complex pharmacodynamic interactions or TRPV1 channel desensitization, but the underlying mechanism remains unclear. Due to technical limitations in assessing peptide concentrations at low doses and the inability to monitor core temperature during behavioral testing, we cannot definitively distinguish between metabolic saturation, thermoregulatory confounds, or specific TRPV1 channel kinetics. Further studies are required to resolve this dose–response complexity.

"Bell-shaped" or "inverse U" dose response is a well-known phenomenon when a higher dose of ligand can change receptor representativity on membranes or other targets could be affected [61–64]. The unstable effect of APHC3 in field postsynaptic potential experiments and after intranasal administration could be the result of the involvement of TRPV1 in multisynaptic pathways comprising excitatory and inhibitory components [44,47] and the ability of APHC3 both to potentiate weak activation and inhibit high-intensity stimulation of TRPV1 [23]

The difference between the effects of intranasal and intramuscular administration of APHC3 compared to AMG517 takes significant attention. The results raise the question of whether behavioral changes in animals are mediated by direct effects on the CNS or by indirect central projections from primary afferent neurons.

Afferent signaling plays a significant role in CNS functioning (Figure 8). For example, a population of sensory neurons expressing the G protein-coupled receptor Mrgprb4 detects mechanical stimulation in mice. Activation of these neurons is required for sexual receptivity and sufficient to induce dopamine release in the brain [65]. Furthermore, peripheral pain, especially neuropathic, can initiate a cascade of events that affect brain function [66–68]. Neuropathic pain models demonstrated significant changes in the hippocampus of experimental animals, including impaired LTP, biochemical changes, and impaired hippocampus-dependent functions [66–68]. On the other hand, stressful conditions activate a cascade of stress hormones that produce physiological changes. Moreover, glucocorticoids (GCs), could enhance pain-like behaviors [69], while other data show that stress exacerbates neuropathic pain [70,71]. This mechanism is unclear, but there is some evidence that dendritic spine structural changes (increased density of mature spines, increased neuronal excitability, and a redistribution of spines) occur in the spinal cord and in higher brain regions, including the hippocampus, after neuropathic pain [72]. However, cortical layer 5 neurons tend to lose dendritic spines after loss of input, which occurs, for example, after thoracic spinal transection [73]. In this way, a decrease in the excitability of the spinal cord reduces the number of excitatory signals entering the brain preventing an increase in neuronal activity, Arc protein accumulation, LTD induction and other biochemical changes.

Therefore, there is a direct link between afferent input signals and CNS functions. A significant number of primary afferent neurons abundantly express TRPV1 channels. Modulators of TRPV1 channels affect terminals of these neurons and produce the second-order neuronal central projections in the spinal cord and medulla, which ultimately reach most levels of the CNS [31]. Both AMG517 and APHC3 significantly reduced the response of animals to heat and other stimuli affecting the TRPV1-mediated pathway [20,24,26].

Therefore, we can suggest that inhibition of TRPV1 in the PNS by AMG517 or APHC3 could change primary afferent signaling and modulate the response of mice to acute stress. Evidently, intramuscular administration of peptide APHC3 and AMG517 produced the significant anxiolytic effect equal to reference drug Fab. Most probably, the effect of APHC3 after intramuscular administration was mediated by the action on afferent neurons (Figure 8). Intranasal administration of peptide had moderate effectiveness only in a certain dose. We consider that the reduced efficacy of the intranasal dose administration compared to intramuscular is not an artifact of poor CNS bioavailability, but rather a distinct pharmacodynamic profile. The biphasic response suggests that optimal anxiolytic effect via the intranasal route occurs within a narrow concentration window.



Figure 8. Pathway linking stress, pain, and anxiety with the peripheral TRPV1 blockade. Stress and pain (peripheral or neuropathic) initiate different pathological signal pathways. Stress hormones can directly exacerbate pain sensitization and neuropathic states. Conversely, chronic pain signaling drives central adaptations—including increased neuronal excitability, synaptic remodeling, and impaired hippocampal long-term potentiation (LTP)—that can lead to anxiety-like behavior. We propose that blocking peripheral TRPV1 channels with APHC3 or AMG517 reduces nociceptive drive to the spinal cord. This decrease in excitatory signaling mitigates central maladaptive changes in the CNS (e.g., prevents aberrant LTD), thereby restoring normal synaptic function (LTP/PPF) and reducing anxiety.

It is important to note that conclusions regarding the main site of action for APHC3 were inferred from the route of administration and the known properties of the blood–brain barrier rather than direct quantification of the peptide in brain tissue. Additionally, the mechanistic basis for the observed 'inverse U-shaped' dose–response curve requires further investigation using sensitive pharmacokinetic assays and integrated physiological monitoring. The molecular size of APHC3 (~6.1 kDa) suggests restricted entry across the blood–brain barrier following systemic administration, and our results are consistent with a potential role for peripheral TRPV1 modulation in driving anxiolysis. However, in the absence of direct brain pharmacokinetic data after i.m. administration or comparative intracerebroventricular administration, a central contribution following intramuscular injection cannot be entirely ruled out.

In this study we found that APHC3, a peptide modulator of TRPV1, can enhance LTP of the CA3-CA1 region at concentrations of 30 and 300 nM, when AMG517, a potent inhibitor of TRPV1, had no effect. Both compounds were able to enhance PPR at certain time intervals. APHC3 and AMG517 produced a significant anxiolytic effect on mice in acute stress models equal to the reference anxiolytic drug Fabomotizole. Peptide APHC3,

both after i.m. and i.n. administration, exhibits a distinct and potentially biphasic anxiolytic efficacy profile. Our data suggest that the anxiolytic effect of TRPV1 antagonists can engage TRPV1-mediated pathways via both the peripheral nervous system and the CNS.

4. Materials and Methods

4.1. Drugs

APHC3 was produced as described previously [74]. Fabomotizole was purchased from Sigma-Aldrich (Moscow, Russia) and AMG517 from Tocris Bioscience (Bristol, UK).

4.2. Animals

Three- to four-month-old male mice C57BL/6 were used in the LTP/PPR experiments. Experiments on acute stress were performed on 8–10-week-old male ICR mice (Animal Breeding Facility Branch of Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Pushchino, Russia) weighing 20–30 g. Animals were housed at room temperature (23 ± 2 °C) in a 12 h light–dark cycle with ad libitum access to food and water.

4.3. Slice Preparation

The mice were anesthetized with isoflurane (1-chloro-2,2,2-trifluoroethyl-difluoromethyl ether) before decapitation. Then the brain was removed from the skull and cut into 350 µm sagittal slices in a slicing solution (125 mM NaCl, 20 mM glucose, 1.25 mM NaH_2PO_4, 2.3 mM KCl, 2.5 mM $NaHCO_3$, 0.8 mM $CaCl_2$, 8 mM $MgCl_2$) with a vibrating microtome (Microm HM 650V; Thermo Fisher Scientific, Waltham, MA, USA). The extended recovery and ionic equilibration of slices were performed by incubation in ACSF solution (Artificial CerebroSpinal Fluid—125 mM NaCl, 20 mM glucose, 1.25 mM NaH_2PO_4, 2.3 mM KCl, 2.5 mM $NaHCO_3$, 2 mM $CaCl_2$, 1 mM $MgCl_2$) for 30 min at 30 °C, followed by 1 h incubation at room temperature. Afterward the slice was placed in an immersion chamber with continuous superfusion (1–3 mL/min) of ACSF. The experiments were carried out at 32 °C. All solutions were saturated with carbogen (95% O_2 and 5% CO_2) and had an osmolarity and pH of 295 ± 5 mOsm and 7.4, respectively.

4.4. Field Potential Recordings

The field excitatory postsynaptic potentials (fEPSPs) were recorded in the striatum radiatum of the hippocampal CA1 area with glass micropipettes filled with ACSF (Huang et al., 2015) [75]. The stimulation electrode was applied to the hippocampal CA3-CA1 area, and stimulation strength was adjusted to half-maximal stimulus intensity when the amplitude of fEPSP was 40–50% of the amplitude where the population spike appeared for the first time. The strength of stimulation was constant during the experiment, usually being 50–150 µA. Short-term synaptic plasticity (the synapse release probability) was studied during the paired stimulation with the following comparison of the ratios of fEPSPs amplitudes. The LTP induction could be started only if the baseline fEPSPs were stable for 15 min. The high-frequency stimulation (HFS, three times 20 pulses at 100 Hz, with a 20 s interval between bursts) was applied to induce LTP. The fEPSPs were recorded after the induction protocol during 60 min. Plasticity value was calculated as a ratio of averaged potentiated fEPSP amplitude (recorded 50–60 min after the HFS) to averaged baseline fEPSP amplitude. The inverse value of the synapse release probability (PPR, paired-pulse ratio) was calculated as the amplitude ratio of the second to first fEPSP. Field potential recordings data were studied with WinWCP v5.8.3. (Strathclyde Electrophysiology Software, Glasgow, Scotland) and Clampfit v11.3 (Axon Instruments Inc.; Union City, CA, USA). Statistical analysis was processed with Origin 2021b (OriginLab Corp., Northampton, MA, USA). All

data are presented as the mean ± SD. The reliability of differences between groups was verified by Student's *t*-test; $p \leq 0.05$ was considered significant, and n corresponds to the number of animals in each set of experiments. To reduce the number of animals, slices obtained from one animal were used across different concentrations of the same compound in this project.

4.5. Assessment of Stress Condition

Before the study, the animals were divided into groups based on the route of administration and doses. For intramuscular administration, the animals were divided into six groups of 16 animals each. Animals from group 1 were administered saline. Animals from groups 2–4 received the APHC3 peptide at doses of 0.01 mg/kg, 0.1 mg/kg, and 1 mg/kg, respectively. The doses for the peptide were selected based on previously published studies on analgesic and anti-inflammatory activity [24,26]. Groups 5 and 6 were administered the comparison drugs Fabomotizole (2.4 mg/kg) and AMG517 (1 mg/kg). For intranasal administration, they were also divided into six groups of 16 animals each. A dose of 0.005 mg/kg for APHC3 was added, and the AMG517 group was excluded. In each group, eight animals were subjected to the elevated plus maze test, and the other eight were used in the light/dark chamber test. All functional tests were conducted 30 min after substance administration.

4.5.1. Elevated Plus Maze Test

The elevated plus maze test is based on rodents' instinctive preference for dark burrows, their natural fear of open spaces, and the possibility of falling from heights. Anxiety indicators recorded for 5 min in the elevated plus maze included the number of exits and the duration of stay in open arms, as well as the ratio of time and number of exits into open and closed arms.

4.5.2. The Light/Dark Chamber Test

The light/dark chamber test of the TSE Multiconditioning System (TSE Systems, Berlin, Germany) also exploits rodents' natural tendency to avoid brightly lit areas. Animals were placed in the brightly lit compartment of a two-chamber light/dark chamber, and the number of transitions between the light and dark compartments and the duration of stay in the light and dark compartments were recorded over a 5 min period.

4.5.3. Statistical Analysis

Statistical analysis was performed using GraphPad Prism 6.0 for Windows (GraphPad Software, La Jolla, CA, USA). Data shown as mean ± SD. The normality of data distribution was determined by the Shapiro–Wilk and Kolmogorov–Smirnov tests. The significance of the data was determined by analysis of variance (one-way ANOVA) followed by Dunnett's test as a post hoc test.

Author Contributions: Conceptualization, V.M.P., I.A.D., A.V.P. and Y.A.A.; methodology, V.A.P., Y.A.L., K.I.Z. and A.V.P.; validation, V.M.P., A.V.P. and Y.A.A.; formal analysis, V.M.P., A.V.P., Y.A.L. and Y.A.A.; investigation, V.M.P., A.Y.F., V.A.P., Y.A.L. and K.I.Z.; resources, I.A.D., A.V.P. and Y.A.A.; data curation, V.M.P., V.A.P., Y.A.L. and Y.A.A.; writing—original draft preparation, V.M.P. and Y.A.A.; writing—review and editing, Y.A.L. and Y.A.A.; visualization, Y.A.L., A.V.P. and Y.A.A.; supervision, Y.A.A.; project administration, I.A.D. and Y.A.A.; funding acquisition, A.V.P. All authors have read and agreed to the published version of the manuscript.

Funding: The experiments on brain slices were funded by the Russian Science Foundation, grant number 24-14-00379 using the equipment of "Primat" Shared Research Facilities. Conceptualization of the project was carried out within the state assignment of NRC "Kurchatov Institute".

Institutional Review Board Statement: This study conforms fully to the World Health Organization's International Guiding Principles for Biomedical Research Involving Animals. All experiments were approved by the Institutional Commission for the Control and Use of Laboratory Animals of the Branch of the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (protocol number: 973/24, date of approval: 12 April 2024) and by the Institutional Animal Care and Use Committee of the Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences (Protocol Number: 353/2023; date of approval: 3 July 2023).

Data Availability Statement: Data is contained within the article.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Martins, D.; Tavares, I.; Morgado, C. "Hotheaded": The role OF TRPV1 in brain functions. *Neuropharmacology* **2014**, *85*, 151–157. [CrossRef]
2. Nilius, B.; Szallasi, A. Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine. *Pharmacol. Rev.* **2014**, *66*, 676–814. [CrossRef] [PubMed]
3. Meza, R.C.; Ancatén-González, C.; Chiu, C.Q.; Chávez, A.E. Transient Receptor Potential Vanilloid 1 Function at Central Synapses in Health and Disease. *Front. Cell. Neurosci.* **2022**, *16*, 864828. [CrossRef] [PubMed]
4. Sjöstedt, E.; Zhong, W.; Fagerberg, L.; Karlsson, M.; Mitsios, N.; Adori, C.; Oksvold, P.; Edfors, F.; Limiszewska, A.; Hikmet, F.; et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. *Science* **2020**, *367*, eaay5947. [CrossRef] [PubMed]
5. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. *Nature* **1997**, *389*, 816–824. [CrossRef]
6. Tognetto, M.; Amadesi, S.; Harrison, S.; Creminon, C.; Trevisani, M.; Carreras, M.; Matera, M.; Geppetti, P.; Bianchi, A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. *J. Neurosci.* **2001**, *21*, 1104–1109. [CrossRef]
7. Baccei, M.L.; Bardoni, R.; Fitzgerald, M. Development of nociceptive synaptic inputs to the neonatal rat dorsal horn: Glutamate release by capsaicin and menthol. *J. Physiol.* **2003**, *549*, 231–242. [CrossRef]
8. Marsch, R.; Foeller, E.; Rammes, G.; Bunck, M.; Kössl, M.; Holsboer, F.; Zieglgänsberger, W.; Landgraf, R.; Lutz, B.; Wotjak, C.T. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. *J. Neurosci.* **2007**, *27*, 832–839. [CrossRef]
9. Gibson, H.E.; Edwards, J.G.; Page, R.S.; Van Hook, M.J.; Kauer, J.A. TRPV1 Channels Mediate Long-Term Depression at Synapses on Hippocampal Interneurons. *Neuron* **2008**, *57*, 746–759. [CrossRef]
10. Abdelhamid, R.E.; Kovács, K.J.; Nunez, M.G.; Larson, A.A. Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors. *Pharmacol. Res.* **2014**, *79*, 21–27. [CrossRef]
11. Terzian, A.L.B.; Aguiar, D.C.; Guimarães, F.S.; Moreira, F.A. Modulation of anxiety-like behaviour by Transient Receptor Potential Vanilloid Type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. *Eur. Neuropsychopharmacol.* **2009**, *19*, 188–195. [CrossRef] [PubMed]
12. Li, H.B.; Mao, R.R.; Zhang, J.C.; Yang, Y.; Cao, J.; Xu, L. Antistress Effect of TRPV1 Channel on Synaptic Plasticity and Spatial Memory. *Biol. Psychiatry* **2008**, *64*, 286–292. [CrossRef] [PubMed]
13. De Miguel, Z.; Haditsch, U.; Palmer, T.D.; Azpiroz, A.; Sapolsky, R.M. Adult-generated neurons born during chronic social stress are uniquely adapted to respond to subsequent chronic social stress. *Mol. Psychiatry* **2019**, *24*, 1178–1188. [CrossRef] [PubMed]
14. Brown, T.E.; Chirila, A.M.; Schrank, B.R.; Kauer, J.A. Loss of interneuron LTD and attenuated pyramidal cell LTP in Trpv1 and Trpv3 KO mice. *Hippocampus* **2013**, *23*, 662–671. [CrossRef]
15. Kasckow, J.W.; Mulchahey, J.J.; Geracioti, T.D. Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* **2004**, *28*, 291–295. [CrossRef]
16. Aguiar, D.C.; Terzian, A.L.B.; Guimarães, F.S.; Moreira, F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. *Psychopharmacology* **2009**, *205*, 217–225. [CrossRef]
17. Gao, M.; Wang, Y.; Liu, L.; Qiao, Z.; Yan, L. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present). *Expert Opin. Ther. Pat.* **2021**, *31*, 169–187. [CrossRef]
18. Gavva, N.R.; Treanor, J.J.S.; Garami, A.; Fang, L.; Surapaneni, S.; Akrami, A.; Alvarez, F.; Bak, A.; Darling, M.; Gore, A.; et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. *Pain* **2008**, *136*, 202–210. [CrossRef]

19. Garami, A.; Shimansky, Y.P.; Rumbus, Z.; Vizin, R.C.L.; Farkas, N.; Hegyi, J.; Szakacs, Z.; Solymar, M.; Csenkey, A.; Chiche, D.A.; et al. Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. *Pharmacol. Ther.* **2020**, *208*, 107474. [CrossRef]
20. Doherty, E.M.; Fotsch, C.; Bannon, A.W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J.; Gavva, N.R.; Katon, J.; Nixey, T.; et al. Novel Vanilloid Receptor-1 Antagonists: 2. Structure−Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate. *J. Med. Chem.* **2007**, *50*, 3515–3527. [CrossRef]
21. Gavva, N.R.; Bannon, A.W.; Surapaneni, S.; Hovland, D.N.; Lehto, S.G.; Gore, A.; Juan, T.; Deng, H.; Han, B.; Klionsky, L.; et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. *J. Neurosci.* **2007**, *27*, 3366–3374. [CrossRef] [PubMed]
22. Kozlov, S.A.; Andreev, Y.A.; Murashev, A.N.; Skobtsov, D.I.; D'yachenko, I.A.; Grishin, E.V. New polypeptide components from the Heteractis crispa sea anemone with analgesic activity. *Russ. J. Bioorganic Chem.* **2009**, *35*, 711–719. [CrossRef] [PubMed]
23. Nikolaev, M.V.; Dorofeeva, N.A.; Komarova, M.S.; Korolkova, Y.V.; Andreev, Y.A.; Mosharova, I.V.; Grishin, E.V.; Tikhonov, D.B.; Kozlov, S.A. TRPV1 activation power can switch an action mode for its polypeptide ligands. *PLoS ONE* **2017**, *12*, e0177077. [CrossRef] [PubMed]
24. Andreev, Y.A.; Kozlov, S.A.; Korolkova, Y.V.; Dyachenko, I.A.; Bondarenko, D.A.; Skobtsov, D.I.; Murashev, A.N.; Kotova, P.D.; Rogachevskaja, O.A.; Kabanova, N.V.; et al. Polypeptide modulators of TRPV1 produce analgesia without hyperthermia. *Mar. Drugs* **2013**, *11*, 5100–5115. [CrossRef]
25. Philyppov, I.B.; Paduraru, O.N.; Andreev, Y.A.; Grishin, E.V.; Shuba, Y.M. Modulation of TRPV1-dependent contractility of normal and diabetic bladder smooth muscle by analgesic toxins from sea anemone Heteractis crispa. *Life Sci.* **2012**, *91*, 912–920. [CrossRef]
26. Logashina, Y.A.; Palikova, Y.A.; Palikov, V.A.; Kazakov, V.A.; Smolskaya, S.V.; Dyachenko, I.A.; Tarasova, N.V.; Andreev, Y.A. Anti-Inflammatory and Analgesic Effects of TRPV1 Polypeptide Modulator APHC3 in Models of Osteo- and Rheumatoid Arthritis. *Mar. Drugs* **2021**, *19*, 39. [CrossRef]
27. Maleeva, E.E.; Palikova, Y.A.; Palikov, V.A.; Kazakov, V.A.; Simonova, M.A.; Logashina, Y.A.; Tarasova, N.V.; Dyachenko, I.A.; Andreev, Y.A. Potentiating TRPA1 by Sea Anemone Peptide Ms 9a-1 Reduces Pain and Inflammation in a Model of Osteoarthritis. *Mar. Drugs* **2023**, *21*, 617. [CrossRef]
28. Kolesova, Y.S.; Stroylova, Y.Y.; Maleeva, E.E.; Moysenovich, A.M.; Pozdyshev, D.V.; Muronetz, V.I.; Andreev, Y.A. Modulation of TRPV1 and TRPA1 Channels Function by Sea Anemones' Peptides Enhances the Viability of SH-SY5Y Cell Model of Parkinson's Disease. *Int. J. Mol. Sci.* **2023**, *25*, 368. [CrossRef]
29. Pavlov, V.M.; Fedotova, A.Y.; Andreev, Y.A.; Palikov, V.A.; Dyachenko, I.A. The Study of TRPV1 Channels of the Central Nervous System and Their Effect on Anxiety in ICR Mice. *Dokl. Biochem. Biophys.* **2024**, *518*, 372–375. [CrossRef]
30. Nazıroğlu, M.; Braidy, N. Thermo-Sensitive TRP Channels: Novel Targets for Treating Chemotherapy-Induced Peripheral Pain. *Front. Physiol.* **2017**, *8*, 1040. [CrossRef]
31. Chahl, L.A. TRPV1 Channels in the Central Nervous System as Drug Targets. *Pharmaceuticals* **2024**, *17*, 756. [CrossRef] [PubMed]
32. Cuevas, J.; Behensky, A.; Deng, W.; Katnik, C. Afobazole modulates neuronal response to ischemia and acidosis via activation of σ-1 receptors. *J. Pharmacol. Exp. Ther.* **2011**, *339*, 152–160. [CrossRef] [PubMed]
33. Neznamov, G.G.; Syunyakov, S.A.; Chumakov, D.V.; Mametova, L.E. Aphobazol—New selective anxyolytic drug. *Zhurnal Nevrol. I Psihiatr. Im. S.S. Korsakova* **2005**, *105*, 35–40.
34. Saffarzadeh, F.; Eslamizade, M.J.; Ghadiri, T.; Modarres Mousavi, S.M.; Hadjighassem, M.; Gorji, A. Effects of TRPV1 on the hippocampal synaptic plasticity in the epileptic rat brain. *Synapse* **2015**, *69*, 375–383. [CrossRef]
35. Popov, A.; Denisov, P.; Bychkov, M.; Brazhe, A.; Lyukmanova, E.; Shenkarev, Z.; Lazareva, N.; Verkhratsky, A.; Semyanov, A. Caloric restriction triggers morphofunctional remodeling of astrocytes and enhances synaptic plasticity in the mouse hippocampus. *Cell Death Dis.* **2020**, *11*, 208. [CrossRef]
36. Jülke, E.M.; Beck-Sickinger, A.G. Peptide therapeutics: Current status and future opportunity with focus on nose-to-brain delivery. *Peptides* **2025**, *188*, 171404. [CrossRef]
37. Majie, A.; Karmakar, V.; Ghosh, A.; Chakraborty, S.; Apurva; Layek, B.; Gorain, B. Advanced intranasal peptide delivery systems for improved management of Alzheimer's disease. *Biomater. Adv.* **2026**, *178*, 214474. [CrossRef]
38. Shiri, M.; Komaki, A.; Oryan, S.; Taheri, M.; Komaki, H.; Etaee, F. Effects of cannabinoid and vanilloid receptor agonists and their interaction on learning and memory in rats. *Can. J. Physiol. Pharmacol.* **2017**, *95*, 382–387. [CrossRef]
39. You, I.J.; Jung, Y.H.; Kim, M.J.; Kwon, S.H.; Hong, S.I.; Lee, S.Y.; Jang, C.G. Alterations in the emotional and memory behavioral phenotypes of transient receptor potential vanilloid type 1-deficient mice are mediated by changes in expression of 5-HT 1A, GABA A, and NMDA receptors. *Neuropharmacology* **2012**, *62*, 1034–1043. [CrossRef]
40. Ngoc, K.H.; Kecskés, A.; Kepe, E.; Nabi, L.; Keeble, J.; Borbély, É.; Helyes, Z. Expression of the Transient Receptor Potential Vanilloid 1 ion channel in the supramammillary nucleus and the antidepressant effects of its antagonist AMG9810 in mice. *Eur. Neuropsychopharmacol.* **2023**, *73*, 96–107. [CrossRef]

41. Malinow, R.; Tsien, R.W. Presynaptic enhancement shown by whole-cell recordings of long-term potentiation in hippocampal slices. *Nature* **1990**, *346*, 177–180. [CrossRef]
42. Scheuber, A.; Miles, R.; Poncer, J.C. Presynaptic Cav2.1 and Cav2.2 differentially influence release dynamics at hippocampal excitatory synapses. *J. Neurosci.* **2004**, *24*, 10402–10409. [CrossRef] [PubMed]
43. Jackman, S.L.; Regehr, W.G. The Mechanisms and Functions of Synaptic Facilitation. *Neuron* **2017**, *94*, 447–464. [CrossRef] [PubMed]
44. Bartley, A.F.; Dobrunz, L.E. Short-term plasticity regulates the excitation/inhibition ratio and the temporal window for spike integration in CA1 pyramidal cells. *Eur. J. Neurosci.* **2015**, *41*, 1402–1415. [CrossRef] [PubMed]
45. Medvedeva, Y.V.; Kim, M.S.; Usachev, Y.M. Mechanisms of prolonged presynaptic Ca^{2+} signaling and glutamate release induced by TRPV1 activation in rat sensory neurons. *J. Neurosci.* **2008**, *28*, 5295–5311. [CrossRef]
46. Goswami, C.; Rademacher, N.; Smalla, K.H.; Kalscheuer, V.; Ropers, H.H.; Gundelfinger, E.D.; Hucho, T. TRPV1 acts as a synaptic protein and regulates vesicle recycling. *J. Cell Sci.* **2010**, *123*, 2045–2057. [CrossRef]
47. Bennion, D.; Jensen, T.; Walther, C.; Hamblin, J.; Wallmann, A.; Couch, J.; Blickenstaff, J.; Castle, M.; Dean, L.; Beckstead, S.; et al. Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system. *Neuropharmacology* **2011**, *61*, 730–738. [CrossRef]
48. Schulz, P.E.; Fitzgibbons, J.C. Differing mechanisms of expression for short- and long-term potentiation. *J. Neurophysiol.* **1997**, *78*, 321–334. [CrossRef]
49. Nater, U.M.; Skoluda, N.; Strahler, J. Biomarkers of stress in behavioural medicine. *Curr. Opin. Psychiatry* **2013**, *26*, 440–445. [CrossRef]
50. Shin, L.M.; Liberzon, I. The neurocircuitry of fear, stress, and anxiety disorders. *Neuropsychopharmacology* **2010**, *35*, 169–191. [CrossRef]
51. Atrooz, F.; Alkadhi, K.A.; Salim, S. Understanding stress: Insights from rodent models. *Curr. Res. Neurobiol.* **2021**, *2*, 100013. [CrossRef]
52. Kraeuter, A.K.; Guest, P.C.; Sarnyai, Z. The Elevated Plus Maze Test for Measuring Anxiety-Like Behavior in Rodents. *Methods Mol. Biol.* **2019**, *1916*, 69–74. [CrossRef]
53. Komada, M.; Takao, K.; Miyakawa, T. Elevated plus maze for mice. *J. Vis. Exp.* **2008**, *22*, 1088. [CrossRef]
54. Bourin, M.; Hascoët, M. The mouse light/dark box test. *Eur. J. Pharmacol.* **2003**, *463*, 55–65. [CrossRef] [PubMed]
55. Rubino, T.; Realini, N.; Castiglioni, C.; Guidali, C.; Viganó, D.; Marras, E.; Petrosino, S.; Perletti, G.; Maccarrone, M.; Di Marzo, V.; et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. *Cereb. Cortex* **2008**, *18*, 1292–1301. [CrossRef] [PubMed]
56. Santos, C.J.P.A.; Stern, C.A.J.; Bertoglio, L.J. Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. *Behav. Pharmacol.* **2008**, *19*, 357–360. [CrossRef]
57. Hakimizadeh, E.; Oryan, S.; Moghaddam, A.H.; Shamsizadeh, A.; Roohbakhsh, A. Endocannabinoid System and TRPV1 Receptors in the Dorsal Hippocampus of the Rats Modulate Anxiety-like Behaviors. *Iran. J. Basic Med. Sci.* **2012**, *15*, 795–802.
58. Meredith, M.E.; Salameh, T.S.; Banks, W.A. Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases. *AAPS J.* **2015**, *17*, 780. [CrossRef]
59. Horta, N.A.; Fernandes, P.; Cardoso, T.S.; Machado, F.S.; Drummond, L.R.; Coimbra, C.C.; Wanner, S.P.; Maria, L.; Castrucci, A.; Poletini, M.O. TRPV1 inactivation alters core body temperature and serum corticosterone levels: Impacts on clock genes expression in the liver and adrenal glands. *J. Therm. Biol.* **2023**, *114*, 103514. [CrossRef]
60. Hai, J.; Kawabata, F.; Uchida, K.; Nishimura, S.; Tabata, S. Intragastric administration of AMG517, a TRPV1 antagonist, enhanced activity-dependent energy metabolism via capsaicin-sensitive sensory nerves in mice. *Biosci. Biotechnol. Biochem.* **2020**, *84*, 2121–2127. [CrossRef]
61. Calabrese, E.J.; Blain, R.B. The hormesis database: The occurrence of hormetic dose responses in the toxicological literature. *Regul. Toxicol. Pharmacol.* **2011**, *61*, 73–81. [CrossRef] [PubMed]
62. Andreev, Y.A.; Osmakov, D.I.; Koshelev, S.G.; Maleeva, E.E.; Logashina, Y.A.; Palikov, V.A.; Palikova, Y.A.; Dyachenko, I.A.; Kozlov, S.A. Analgesic Activity of Acid-Sensing Ion Channel 3 (ASIC3) Inhibitors: Sea Anemones Peptides Ugr9-1 and APETx2 versus Low Molecular Weight Compounds. *Mar. Drugs* **2018**, *16*, 500. [CrossRef] [PubMed]
63. Kalinovskii, A.P.; Pushkarev, A.P.; Mikhailenko, A.D.; Kudryavtsev, D.S.; Belozerova, O.A.; Shmygarev, V.I.; Yatskin, O.N.; Korolkova, Y.V.; Kozlov, S.A.; Osmakov, D.I.; et al. Dual Modulator of ASIC Channels and GABAA Receptors from Thyme Alters Fear-Related Hippocampal Activity. *Int. J. Mol. Sci.* **2023**, *24*, 13148. [CrossRef] [PubMed]
64. Logashina, Y.A.; Lubova, K.I.; Maleeva, E.E.; Palikov, V.A.; Palikova, Y.A.; Dyachenko, I.A.; Andreev, Y.A. Analysis of Structural Determinants of Peptide MS 9a-1 Essential for Potentiating of TRPA1 Channel. *Mar. Drugs* **2022**, *20*, 465. [CrossRef]
65. Elias, L.J.; Succi, I.K.; Schaffler, M.D.; Foster, W.; Gradwell, M.A.; Bohic, M.; Fushiki, A.; Upadhyay, A.; Ejoh, L.L.; Schwark, R.; et al. Touch neurons underlying dopaminergic pleasurable touch and sexual receptivity. *Cell* **2023**, *186*, 577–590.e16. [CrossRef]

66. Kodama, D.; Ono, H.; Tanabe, M. Altered hippocampal long-term potentiation after peripheral nerve injury in mice. *Eur. J. Pharmacol.* **2007**, *574*, 127–132. [CrossRef]
67. Ren, W.J.; Liu, Y.; Zhou, L.J.; Li, W.; Zhong, Y.; Pang, R.P.; Xin, W.J.; Wei, X.H.; Wang, J.; Zhu, H.Q.; et al. Peripheral Nerve Injury Leads to Working Memory Deficits and Dysfunction of the Hippocampus by Upregulation of TNF-α in Rodents. *Neuropsychopharmacology* **2011**, *36*, 979. [CrossRef]
68. Tyrtyshnaia, A.; Manzhulo, I. Neuropathic Pain Causes Memory Deficits and Dendrite Tree Morphology Changes in Mouse Hippocampus. *J. Pain Res.* **2020**, *13*, 345. [CrossRef]
69. Blackburn-Munro, G.; Blackburn-Munro, R. Pain in the brain: Are hormones to blame? *Trends Endocrinol. Metab.* **2003**, *14*, 20–27. [CrossRef]
70. Li, M.J.; Liu, L.Y.; Chen, L.; Cai, J.; Wan, Y.; Xing, G.G. Chronic stress exacerbates neuropathic pain via the integration of stress-affect-related information with nociceptive information in the central nucleus of the amygdala. *Pain* **2017**, *158*, 717–739. [CrossRef]
71. Alexander, J.K.; DeVries, A.C.; Kigerl, K.A.; Dahlman, J.M.; Popovich, P.G. Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation. *Brain. Behav. Immun.* **2009**, *23*, 851–860. [CrossRef]
72. Stratton, H.J.; Khanna, R. Sculpting Dendritic Spines during Initiation and Maintenance of Neuropathic Pain. *J. Neurosci.* **2020**, *40*, 7578–7589. [CrossRef]
73. Ghosh, A.; Peduzzi, S.; Snyder, M.; Schneider, R.; Starkey, M.; Schwab, M.E. Heterogeneous spine loss in layer 5 cortical neurons after spinal cord injury. *Cereb. Cortex* **2012**, *22*, 1309–1317. [CrossRef]
74. Esipov, R.S.; Makarov, D.A.; Stepanenko, V.N.; Kostromina, M.A.; Muravyova, T.I.; Andreev, Y.A.; Dyachenko, I.A.; Kozlov, S.A.; Grishin, E.V. Pilot production of the recombinant peptide toxin of Heteractis crispa as a potential analgesic by intein-mediated technology. *Protein Expr. Purif.* **2018**, *145*, 71–76. [CrossRef]
75. Huang, Y.; Chen, J.; Chen, Y.; Zhuang, Y.; Sun, M.; Behnisch, T. The neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) alters hippocampal excitatory synaptic transmission by modulation of the GABAergic system. *Front. Cell. Neurosci.* **2015**, *9*, 299. [CrossRef]